Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKB-122 as Adjunct Therapy in Autoimmune Hepatitis
NCT04371718Phase 2Unknown
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in autoimmune hepatitis (AIH) (4 arms), sponsored by TaiwanJ Pharmaceuticals Co., Ltd. Primary endpoint: Reduction of inflammation in Autoimmune Hepatitis at 24 months. Status: unknown.
02
Drugs
naltrexone
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT04371718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371718.